To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
Public ClinicalTrials.gov record NCT01768572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.
Study identification
- NCT ID
- NCT01768572
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Interventions
- sarilumab SAR153191 (REGN88) Drug
- tocilizumab Drug
- hydroxychloroquine Drug
- methotrexate Drug
- sulfasalazine Drug
- leflunomide Drug
- subcutaneous placebo Drug
- intravenous placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2013 (Type not available)
- Primary completion
- Oct 2014 (Actual)
- Completion
- Oct 2014 (Actual)
- Last update posted
- Jun 26, 2017
2013 – 2014
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840152 | Huntsville | Alabama | 35801 | — |
| Investigational Site Number 840151 | Colorado Springs | Colorado | 80903 | — |
| Investigational Site Number 840153 | Aventura | Florida | 33180 | — |
| Investigational Site Number 840033 | Fort Lauderdale | Florida | 33334 | — |
| Investigational Site Number 840048 | Miami | Florida | 33155 | — |
| Investigational Site Number 840155 | Palm Harbor | Florida | 34684 | — |
| Investigational Site Number 840013 | Wheaton | Maryland | 20902 | — |
| Investigational Site Number 840154 | Boston | Massachusetts | 02115 | — |
| Investigational Site Number 840150 | Lansing | Michigan | 48910 | — |
| Investigational Site Number 840062 | Reading | Pennsylvania | 19611 | — |
| Investigational Site Number 840038 | Austin | Texas | 78705 | — |
| Investigational Site Number 840022 | Dallas | Texas | 75235 | — |
| Investigational Site Number 840156 | Dallas | Texas | 75246 | — |
| Investigational Site Number 840074 | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01768572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01768572 live on ClinicalTrials.gov.